Triple Threat Communications
140 East Ridgewood Ave.
Paramus, New Jersey 07652
Year Founded
North American Revenue
Full-time Employees
Number of Clients
North America
Paramus, NJ
Executives & Senior Management
Tim Frank
Owner/managing partner
Aleisha Ivey
Adam Cohen
Head of creative, art
Senior Management
Tim Frank Owner/managing partner
Adam Cohen Head of creative, art
Jeff Perino Head of creative, copy
Bob Hogan Head of consumer services
Aleisha Ivey Comptroller
Jesse Pease Head of digital
Meher Khambata Head of project management and production
Recent Executive Hires
Steve McGinniss Omnichannel strategist
Agency 100 Movie Poster
Triple Threat Poster
Capabilities/Services Offered
Professional Consumer Med-ed Public Health Data/Analytics
New Services
Omnichannel marketing expertise
2020 Accounts
Client Roster
AstraZeneca Sobi Innocoll
Existing Clients
New Clients
Creative Samples

Description: Triple Threat Communications worked with AstraZeneca to develop the Protect Life campaign for Farxiga (dapagliflozin).
• Highlights the groundbreaking new chronic kidney disease (CKD) Indication for Farxiga
• Creates stopping power by showing a gripping image of a patient living life while superimposed over a threat of dialysis and CV or renal death
• Provides a compelling call-to-action to prescribe Farxiga and protect patients against CKD — so they can live life

Description: Triple Threat Communications worked with Innocoll to develop a launch campaign for Xaracoll (bupivacaine HCI) implant, a new product for postsurgical pain relief.
• A strong headline and arresting visual encourages physicians (primarily general surgeons) to see pain relief placed directly at the source of pain
• showcases the new campaign while providing a targeted look at a transformative drug-device combination product

Company: Sobi
Product: Synagis (palivizumab)
Description: This high-definition MOD-MOA video vividly tells the molecular story of
• a harmful virus, i.e., Respiratory Syncytial Virus or RSV, which causes 16 times more hospitalizations than the flu in infants under 1 year of age
• a humanized monoclonal antibody that has protected millions of high-risk infants from RSV worldwide since 1998